These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 8603014)

  • 1. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation.
    Simioni P; Scarano L; Gavasso S; Sardella C; Girolami B; Scudeller A; Girolami A
    Br J Haematol; 1996 Feb; 92(2):435-41. PubMed ID: 8603014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Activated Protein C Response Rates Reduce the Thrombotic Risk of Factor V Leiden Carriers But Not of Prothrombin 20210G>A Carriers.
    Rühl H; Berens C; Winterhagen FI; Reda S; Müller J; Oldenburg J; Pötzsch B
    Circ Res; 2019 Aug; 125(5):523-534. PubMed ID: 31314700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
    Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
    Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor V Leiden in Greek thrombophilic patients: relationship with activated protein C resistance test and levels of thrombin-antithrombin complex and prothrombin fragment 1 + 2.
    Lambropoulos AF; Foka Z; Makris M; Daly M; Kotsis A; Makris PE
    Blood Coagul Fibrinolysis; 1997 Nov; 8(8):485-9. PubMed ID: 9491265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heightened thrombin generation in individuals with resistance to activated protein C.
    Martinelli I; Bottasso B; Duca F; Faioni E; Mannucci PM
    Thromb Haemost; 1996 May; 75(5):703-5. PubMed ID: 8725708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Markers of activated coagulation in patients with factor V Leiden and/or G20210A prothrombin gene mutation.
    Gouin-Thibault I; Arkam R; Nassiri S; de la Tourette A; Conard J; Horellou MH; Elalamy I; Samama MM
    Thromb Res; 2002 Jul; 107(1-2):7-11. PubMed ID: 12413582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency.
    Zöller B; Holm J; Svensson P; Dahlbäck B
    Thromb Haemost; 1996 Feb; 75(2):270-4. PubMed ID: 8815575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of elevated levels of prothrombin fragment 1+2 and Arg506 to Gln mutation in patients with a history of ischemic stroke.
    De Lucia D; Papa ML; Ammendola F; Pezzella S; Del Giudice V; Marotta R; Renis V; Di Mauro C; Maisto G; Masi S; Nina P; Franco A; Schisano G
    J Neurosurg Sci; 1999 Mar; 43(1):45-50; discussion 50-1. PubMed ID: 10494665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation.
    De Stefano V; Martinelli I; Mannucci PM; Paciaroni K; Chiusolo P; Casorelli I; Rossi E; Leone G
    N Engl J Med; 1999 Sep; 341(11):801-6. PubMed ID: 10477778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients.
    Födinger M; Mannhalter C; Pabinger I; Koizar D; Rintelen C; Hörl WH; Sunder-Plassmann G
    Nephrol Dial Transplant; 1996 Apr; 11(4):668-72. PubMed ID: 8671856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred.
    Sartori MT; Simioni P; Patrassi GM; Theodoridis P; Tormene D; Girolami A
    Clin Appl Thromb Hemost; 2000 Jan; 6(1):36-40. PubMed ID: 10726047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and laboratory expression of associated thrombophilic conditions (homozygous/heterozygous factor V Leiden mutation and heterozygous prothrombin variant 20210A) in an Italian family.
    Simioni P; Tormene D; Luni S; Caldato M; Girolami A
    Blood Coagul Fibrinolysis; 2000 Jun; 11(4):379-84. PubMed ID: 10847426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood coagulation at the site of microvascular injury in healthy and coumadin-treated subjects heterogenous for factor V Leiden mutation.
    Undas A; Brzezinska-Kolarz B; Orfeo T; Brummel-Ziedins K; Musial J; Szczeklik A; Mann KG
    Thromb Haemost; 2007 Nov; 98(5):1024-30. PubMed ID: 18000607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
    Gessoni G; Valverde S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prothrombin fragment F1+2 is not predictive for recurrent venous thromboembolism.
    Kyrle PA; Eichinger S; Pabinger I; Stümpflen A; Hirschl M; Bialonczyk C; Schneider B; Mannhalter C; Melichart M; Traxler G; Weltermann A; Speiser W; Lechner K
    Thromb Haemost; 1997 May; 77(5):829-33. PubMed ID: 9184387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation.
    Brugge JM; Simioni P; Bernardi F; Tormene D; Lunghi B; Tans G; Pagnan A; Rosing J; Castoldi E
    J Thromb Haemost; 2005 Dec; 3(12):2695-702. PubMed ID: 16359508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A.
    Lijfering WM; Middeldorp S; Veeger NJ; Hamulyák K; Prins MH; Büller HR; van der Meer J
    Circulation; 2010 Apr; 121(15):1706-12. PubMed ID: 20368522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combined hemostatic defects in family members of symptomatic carriers of Leiden mutations of factor V].
    Lewandowski K; Rozek M; Turowiecka Z; Markiewicz WT; Zawilska K
    Pol Arch Med Wewn; 1998 Mar; 99(3):211-7. PubMed ID: 9760807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypercoagulability markers in young asymptomatic heterozygous carriers of factor V Leiden (G1691A) or prothrombin (G20210A) variant.
    Godoi LC; Fernandes AP; Vieira LM; Melgaço DA; de Bastos M; Ribeiro Mde F; Carvalho Md; Dusse LM
    Clin Chim Acta; 2006 Mar; 365(1-2):304-9. PubMed ID: 16256098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of venous thromboembolism in carriers of factor V Leiden with a concomitant inherited thrombophilic defect: a retrospective analysis.
    Meinardi JR; Middeldorp S; de Kam PJ; Koopman MM; van Pampus EC; Hamulyák K; Prins MH; Büller HR; van der Meer J
    Blood Coagul Fibrinolysis; 2001 Dec; 12(8):713-20. PubMed ID: 11734673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.